ProCE Banner Series

The Evolving Understanding of IgA Nephropathy: Implications of New Treatment for Managed Care Pharmacy Professionals

In this live symposium, expert faculty will discuss IgA nephropathy, pathophysiology, new and emerging therapies, and methods to address economic and disease burden in the managed care setting. Register today!

Join us from 6:00 PM – 6:30 PM Eastern Time (ET) for in-person registration or at 6:30 PM ET online when the symposium begins. 

To Register: Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.



  ACPE
Credits Available

1.5

Who Should Attend

This program is intended for managed care pharmacists and specialty and clinical pharmacists who care for patients with IgAN, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

All Events

The Evolving Understanding of IgA Nephropathy: Implications of New Treatment for Managed Care Pharmacy Professionals

Past Events

October

17

2023

6:00 PM - 8:00 PM Eastern Time (ET)

In-personVirtual

Orlando World Center Marriott, 8701 World Center Drive, Orlando, Florida 32821

Faculty

ProCE Banner Faculty
Michelle M. Richardson, PharmD, BCPS

Special and Scientific Staff
Tufts Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

ProCE Banner Faculty
Silvia Titan, MD, PhD

Senior Associate Consultant
Nephrology Division, Mayo Clinic
Rochester, Minnesota

Topics

In-person Registration: 6:00 PM – 6:30 PM Eastern Time (ET)

Presentation: 6:30 - 8:00 PM Eastern Time (ET)

  • Welcome and Baseline Polling
  • Progression Risk of IgA Nephropathy
  • Latest Clinical Evidence for the Management of IgA Nephropathy
  • New and Emerging Therapies for IgA Nephropathy
  • Managed Care Strategies to Impact Economic and Disease Burden of IgA Nephropathy
  • Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Program Overview
The primary purpose of this program is to arm healthcare professionals with the tools to address the economic impact of IgA nephropathy by providing a thorough overview of disease prevalence, new and emerging treatment options, and discussing strategies for optimizing patient outcomes, medication access, and healthcare delivery.

Goal Statement
The goal of this program is to improve the knowledge and competence of pharmacist learners about new and emerging therapies for IgAN.

Target Audience
This program is intended for managed care pharmacists and specialty and clinical pharmacists who care for patients with IgAN, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

Learning Objectives

  • Describe the current understanding of the pathogenesis and pathophysiology of IgA nephropathy in alignment with available and potential treatment targets
  • Analyze the pharmacology and clinical outcomes data for recently FDA-approved and emerging therapies to facilitate optimal integration into treatment algorithms/clinical pathways
  • Examine the economic and clinical burden of IgAN and opportunities for managed care interventions to improve costs and patient outcomes

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-027-L01-P has been assigned to this live application-based activity (initial release date 10/17/2023). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC

Supported by an educational grant from Calliditas Therapeutics.